(151a) Towards Sustainable Biopharmaceutical Production Via Single-Use Technologies

Advanced therapeutics such as monoclonal antibodies (mAbs) are among the most powerful tools for improving global health. These proteins, from rare cancers to viral infections, enable us to fight the most challenging diseases. Therefore, a more equitable production and distribution of mAbs is essential for global health. As demand for these therapeutics increases, so does the environmental impact of their manufacturing processes. Today, addressing these ecological impacts has become a top priority of technology providers and biopharmaceutical manufacturers.

Single-use technologies generate significant opportunities for process intensification and more robust and cost-effective biopharmaceutical manufacturing which can result in reduced facility footprint and energy consumption. However, the increasing amount of consumable waste produced in the sector is concerning.

In this talk, we review the potential environmental impacts of mAbs biomanufacturing and quantify how different process intensification strategies contribute to more sustainable production. Furthermore, you will hear about Sartorius's contribution towards “Sustainability Development Goals”, “New Plastic Economy”, and examples of circularity opportunities, potentially, applicable to the biopharmaceutical industry.